Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial

Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial

Background: WHO recommends daily co-trimoxazole for children born to HIV-infected mothers from 6 weeks of age until breastfeeding cessation and exclusion of HIV infection. We have previously reported on the effectiveness of continuation of co-trimoxazole prophylaxis up to age 2 years in these child...

Full description

Bibliographic Details
Main Authors: Dr. Jaco Homsy, MD, Grant Dorsey, MD, Emmanuel Arinaitwe, MD, Humphrey Wanzira, MBChB, Abel Kakuru, MBChB, Victor Bigira, MBChB, Mary Muhindo, MBChB, Prof. Moses R Kamya, MD, Taylor G Sandison, PhD, Jordan W Tappero, MD
Format: Article
Language:English
Published: Elsevier 2014-12-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X14703298

Similar Items

Similar Items